PTC
MRNA icon

Philadelphia Trust Company’s Moderna MRNA Stock Holding History

Philadelphia Trust Company’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,180
Closed -$259K – 254
2024
Q2 		$259K Hold
2,180
– – 0.02% 193
2024
Q1 		$232K Hold
2,180
– – 0.02% 207
2023
Q4 		$217K Sell
2,180
-325
-13% -$27.3K 0.02% 207
2023
Q3 		$259K Hold
2,505
– – 0.03% 190
2023
Q2 		$304K Hold
2,505
– – 0.03% 184
2023
Q1 		$385K Hold
2,505
– – 0.04% 173
2022
Q4 		$450K Hold
2,505
– – 0.05% 159
2022
Q3 		$296K Sell
2,505
-100
-4% -$15.2K 0.03% 181
2022
Q2 		$372K Sell
2,605
-235
-8% -$33.6K 0.04% 167
2022
Q1 		$489K Sell
2,840
-150
-5% -$25.3K 0.04% 167
2021
Q4 		$759K Sell
2,990
-375
-11% -$110K 0.06% 146
2021
Q3 		$1.29M Sell
3,365
-50
-1% -$18.4K 0.1% 115
2021
Q2 		$802K Buy
3,415
+315
+10% +$56.3K 0.06% 151
2021
Q1 		$406K Buy
3,100
+20
+0.6% +$2.9K 0.03% 180
2020
Q4 		$322K Buy
+3,080
New +$312K 0.03% 179
2020
Q3 		– Sell
-4,255
Closed -$273K – 198
2020
Q2 		$273K Buy
+4,255
New +$233K 0.03% 159

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Philadelphia Trust Company's MRNA Position: Q3 2024 in Review

Philadelphia Trust Company sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,180 shares — an estimated $259K sold.

Philadelphia Trust Company first reported a position in MRNA in Q2 2020 and held it in 16 quarters. The position peaked at $1.29M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Philadelphia Trust Company reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Philadelphia Trust Company sold 2,180 Moderna shares in Q3 2024, an estimated $259K.
  • Philadelphia Trust Company first reported a position in Moderna in Q2 2020 and held it in 16 quarters.
  • Philadelphia Trust Company's Moderna position peaked at $1.29M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Philadelphia Trust Company's 13F filing for Q3 2024, filed 13 Nov 2024.